High-risk human papillomavirus (HPV) is a major causative agent of cervical cancer and the E6 and E7 genes encode the major HPV oncoproteins. The E7 protein from high-risk HPV types alters cell cycle progression and represses genes encoding components of the antigenpresentation pathway, suggesting a role for E7 in tumour immune evasion. We show that knockdown of E7 expression in HPV16-and HPV18-transformed cervical carcinoma cells by RNA interference increased expression of major histocompatibility complex (MHC) class I at the cell surface and reduced susceptibility of these cells to natural killer (NK) cells. Tetracycline-regulated induction of HPV16 E7 resulted in reduced expression of cell surface MHC class I molecules and increased NK cell killing. Our results suggest that, for HPV-associated malignancies, reduced MHC class I expression is the result of an active immune evasion strategy that has evolved to assist viral replication. The high-risk human papillomavirus (HPV) types 16 (HPV16) and 18 (HPV18) have a strong association with the incidence of cervical cancer, with at least 90% of cervical adenocarcinomas harbouring HPV16 or HPV18 DNA (Walboomers et al., 1999) . The E6 and E7 oncogenes are continuously expressed following cellular transformation and in cervical cancer tissues while expression of the E5 gene contributes to transformation but is not expressed in cervical tumours (Howley and Lowy, 2007) . Many viruses and tumours evade the T-cell-mediated immune response, primarily by reducing the levels of surface MHC class I, thus reducing the presentation of viral/tumour antigens (Garcia-Lora et al., 2003; Hewitt, 2003) . We have previously shown that the E7 oncoproteins of the high-risk HPV16 and 18 types are able to repress the activity of promoters encoding components of the MHC class I antigen processing and presentation pathway (Georgopoulos et al., 2000) and recent data further suggest that HPV16 E7 interacts with the MHC class I heavy chain promoter in HPV16-transformed human cells (Li et al., 2006) . Here, we have used two complementary approaches to evaluate the effect of HPV16 and 18 E7 expression on the levels of cell-surface MHC class I molecules and consequent effects on natural killer (NK) cell recognition.
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The high-risk human papillomavirus (HPV) types 16 (HPV16) and 18 (HPV18) have a strong association with the incidence of cervical cancer, with at least 90% of cervical adenocarcinomas harbouring HPV16 or HPV18 DNA (Walboomers et al., 1999) . The E6 and E7 oncogenes are continuously expressed following cellular transformation and in cervical cancer tissues while expression of the E5 gene contributes to transformation but is not expressed in cervical tumours (Howley and Lowy, 2007) . Many viruses and tumours evade the T-cell-mediated immune response, primarily by reducing the levels of surface MHC class I, thus reducing the presentation of viral/tumour antigens (Garcia-Lora et al., 2003; Hewitt, 2003) . We have previously shown that the E7 oncoproteins of the high-risk HPV16 and 18 types are able to repress the activity of promoters encoding components of the MHC class I antigen processing and presentation pathway (Georgopoulos et al., 2000) and recent data further suggest that HPV16 E7 interacts with the MHC class I heavy chain promoter in HPV16-transformed human cells (Li et al., 2006) . Here, we have used two complementary approaches to evaluate the effect of HPV16 and 18 E7 expression on the levels of cell-surface MHC class I molecules and consequent effects on natural killer (NK) cell recognition.
In the first approach, E7 expression was reduced in HPV-transformed cells by transfection of an E7-specific short interfering RNA (siRNA) molecule (Jiang and Milner, 2002; Hall and Alexander, 2003) . HPV16-transformed cells (SiHa and CaSki) and HPV18-transformed cells (HeLa) were mock-transfected or transfected with E7-specific or control siRNAs and the level of E7 mRNA analysed 72 h post-transfection by quantitative real-time RT-PCR ( Figure 1a ). This showed that the E7-specific siRNA reduced E7 mRNA sequences by approximately 90% in the HPV16-and HPV18-transformed cell lines. Treatment of the three HPV-transformed cell lines with E7-specific siRNA induced growth arrest and profound morphological changes in transfected cells, as described previously (Hall and Alexander, 2003) ; however, these effects were not observed with control siRNA molecules or in non-HPV-transformed HaCaT cells (Supplementary Figure 1) .
This system of siRNA-transfected cells was therefore used to examine modulation of cell-surface MHC class I molecules using flow cytometry. Knockdown of E7 in SiHa, CaSki and HeLa cells resulted in a significant increase (approximately 50-70% compared to mocktransfected cells) in cell-surface MHC class I levels after 72 h compared to controls (Figures 1b and c) . Statistically significant changes in cell-surface MHC class I expression were found only in the HPV-transformed cell lines transfected with E7-specific siRNA. Furthermore, increases in cell surface MHC class I expression were found in HPV16-and HPV18-transformed cells. Neither control siRNA nor E7-specific siRNA produced alterations in cell-surface MHC class I levels when transfected into non-HPV transformed HaCaT cells (Figures 1b  and c) . The expression of CD46, which is ubiquitously expressed on the surface of human cells, was not significantly altered following control or E7 siRNA transfection in HaCaT or HPV-transformed cells (Supplementary Figure  2) . These data indicate that knockdown of E7 in bona fide HPV-transformed cervical carcinoma cell lines results in significant and specific increases in cell-surface MHC class I molecules.
Since E7 and E6 proteins are synthesized from a bicistronic mRNA in HPV-transformed cells (Tang et al., 2006) , it might be argued that knockdown of E7 mRNA sequences also reduces E6 expression and that the experiments described above do not unambiguously assign a role for E7 in MHC class I regulation. To address this question, a second experimental approach was adopted which involved the expression of exogenous HPV16 E7 in the human osteosarcoma cell line U2OS. Two stable cell lines were studied (Kaznelson et al., 2004) , one isolated following transfection with the control tet-regulated pUHD (tet-off) plasmid vector (termed U2OS-tet off) and the other cell line derived by transfection with a plasmid containing the HPV16 E7 open reading frame under the control of the tet-off promoter (termed U2OS-E7). Removal of tetracycline results in the expression of the E7 mRNA in U2OS-E7 cells, which can be qualitatively detected by RT-PCR at 24, 48 and 72 h after induction (Figure 2a ). No E7 mRNA was found in either U2OS-E7 cells in the presence of tetracycline or in U2OS-tet off cells in the presence or absence of tetracycline. Expression of the induced E7 protein in U2OS-E7 cells was previously shown by western Figure 1 Effect of E7 knockdown on cell surface MHC class I molecules in HPV16-and HPV18-transformed cells. (a) Real-time PCR analysis of HPV16 E7 mRNA in SiHa, CaSki and HPV18 E7 mRNA in HeLa cells 72 h after siRNA treatment. cDNA was synthesized from total RNA as described (Bottley et al., 2005) and real-time PCR was performed using an ABI7900 cycler. Primers used for HPV16 E7 mRNA were as described previously (Pett et al., 2006) and real-time PCR was performed using the SyBr Green system (ABI, Foster City, CA, USA). HPV18 E7 mRNA was assayed using the Roche Universal Probe system (Roche Diagnostics Ltd, Lewes, UK). Expression was determined relative to GAPDH and mock-transfected cells by the 2 ÀDDCt method. Error bars represent 1 s.d. derived from three experiments. (b) Flow cytometric analysis of cell-surface MHC class I molecules using W6/32 antibody, which detects the classical MHC class I molecules HLA-A, -B and -C (solid line) or an isotype-matched control antibody (dotted line) in mocktransfected cells (grey filled histograms) or cells transfected with control siRNA (Qiagen, Hilden, Germany; grey line histograms) or E7 siRNA (black line histograms). E7 siRNAs were as described previously for HPV16 (Jiang and Milner, 2002) and HPV18 (Hall and Alexander, 2003) . HeLa cells were transfected with either the HPV18 E7 or control siRNA whereas the remaining cell lines were transfected with the HPV16 E7 or control siRNA. blotting at higher levels than E7 in HPV16-transformed CaSki cells, whereas no E7 protein was observed in control U2OS-tet off cells (Kaznelson et al., 2004) .
The expression of cell-surface MHC class I molecules was analysed after induction of E7 expression using flow cytometry. A reduction in cell-surface MHC class I levels was observed following tetracycline withdrawal in U2OS-E7 cells but not in U2OS-tet off cells (Figure 2b ). This decrease in cell-surface MHC class I levels was time-dependent up to 72 h (Figure 2c) , however, analysis of cell-surface MHC class I expression at later time points did not show any further reduction (data not Figure 3 Susceptibility of cells to NK killing following induction or knockdown of E7. (a) Effect of E7 induction on cell killing mediated by NK cells over a range of effector/target (E/T) ratios after 6 h co-culture. Cytotoxicity by peripheral blood-derived NK cells was assessed using flow cytometry as described in the text. The results shown are the values of average NK-mediated cell death derived from four experiments and the error bars at an E/T ratio of 20 show 1 s.d. The P-value was derived by Student's t-test, comparing induced versus uninduced U2OS-E7 cells. There were no significant differences in killing at lower E:T ratios. (b) Effect of siRNA-induced E7 knockdown on SiHa cell killing mediated by NK cells over a range of E/T ratios after 6 h co-culture. The results shown are the values of average NK-mediated cell death derived from four experiments. The error bars at an E/T ratio of 20 show 1 s.d. The P-value was derived by Student's t-test, comparing E7 siRNA-transfected with mock-transfected cells. There were no significant differences in killing at lower E/T ratios. Figure 2 Cell-surface expression of MHC class I molecules following induction of E7 expression. (a) Reverse transcription-PCR analysis of HPV16 E7 mRNA in U2OS-E7 and U2OS-tet off cells. Samples were analysed at various times in the presence (noninduced) or absence (induced) of tetracycline in culture media. Total RNA was extracted and cDNA synthesized as described previously (Bottley et al., 2005) and PCR performed with E7 primers as reported previously (Berger et al., 2002) shown). Overall, compared to the control U2OS-tet off cells, a statistically significant decrease of approximately 30% was observed at 72 h post-induction (Figure 2d ). It might be argued that the decreased level of MHC class I molecules is a cellular response to protein overexpression. To address this issue, we analysed cell-surface MHC class I expression in the WT8 cell line, which is a U2OS cell line in which a fusion protein of Polo-like kinase 1 (Plk-1) and YFP is expressed following tetracycline withdrawal (Jackman et al., 2003) . No alteration in MHC class I expression was observed in WT8 cells in the absence of tetracycline (Figure 2d ), although YFP expression was readily detected (data not shown), thus excluding a non-specific alteration in MHC class I expression due to expression of an exogenous protein. Furthermore, CD46 expression was not significantly altered by tetracycline removal in control U2OS-tet off, U2OS-E7 or WT8 cells (Figure 2d ), indicating that E7 (or Plk-1-YFP) expression did not have general downregulatory effects on cell-surface proteins. Overall, these results show that induction of E7 expression results in a specific decrease in cell-surface MHC class I levels.
Reduction in cell surface MHC class I molecules will impair T-cell recognition. However, NK cells express inhibitory receptors which bind to MHC class I molecules and a reduction in MHC class I levels thus reduces inhibitory signalling and favours NK cell activation (Moretta and Moretta, 2004; Lanier, 2005) . Thus, E7 induction resulting in a reduction in cell surface MHC class I (Figure 2 ) would be predicted to lead to an increase in the susceptibility to NK killing. In contrast, a reduction in E7 and increased cell surface MHC class I expression (Figure 1 ) would lead to decreased NK cell killing. We, therefore, tested the functional consequence of modulating E7 expression on the susceptibility of cells to NK killing.
Peripheral blood mononuclear cells were isolated from healthy donors on a Ficoll gradient and NK cells selected from the peripheral blood mononuclear cells using indirect magnetic immunoselection (Bottley et al., 2007) . The NK cells were cultured in the presence of 50 units/ml -1 of interleukin (IL)-2 for 5-7 days and used in a flow cytometric-based killing assay. Briefly, NK cells (effector cells) were labelled with carboxyfluorescein succinimidyl ester (CFSE) and cocultured with target cells at different effector/ target ratios for 5 h at 37 1C and then the cells were stained with propidium iodide (PI). Dead or dying target cells become permeable to PI and have a PI þ , CFSE-phenotype which was quantitated by flow cytometry. Controls without NK cells were used as a measure of spontaneous cell death. As a positive control for NK cell killing, we used the K562 target cell line. This erythroleukaemic cell line is very sensitive to NK cell killing due to its very low level expression of cell surface MHC class I (Bottley et al., 2005) and is a standard control in this type of assay. When E7 expression was induced in U2OS cells, there was a statistically significant increase in susceptibility to NK cells compared to controls ( Figure 3A ; P ¼ 0.038 at an E/T ratio of 20:1, comparing E7-expressing U2OS cells to non-expressing cells). When E7 expression was knocked down in HPV-transformed SiHa cells, there was a statistically significant decrease in susceptibility to NK cells ( Figure 3B ; P ¼ 0.049 at an E/T ratio of 20:1, comparing E7-specific siRNA to control siRNA-treated cells). These results are consistent with the observed modulation of cell surface MHC class I expression by HPV E7 shown by E7 inhibition and E7 induction (Figures 1 and 2) . The E1A oncogene from adenovirus (Ad) 12 also inhibits MHC class I expression via repression of promoter activity (Proffitt et al., 1994; Georgopoulos et al., 2000) . The 50-70% increase in cell surface MHC molecules following inhibition of E7 expression observed here (Figure 1c ) is similar in magnitude to the 30% increase observed following reduction of expression of Ad12 E1A using antisense oligodeoxynucleotides (Zhao and Ricciardi, 2006) . We have previously shown that the reduced levels of cell surface MHC class I found on Ad12-transformed cells are associated with greater susceptibility to human NK cells than Ad5-transformed cells which have higher levels of cell surface MHC class I (Bottley et al., 2005) .
NK cells are regulated by several molecules expressed by target cells in addition to the classical MHC class I molecules. The non-classical MHC class I molecule HLA-E inhibits NK cell activity via interaction with CD94/NKG2A heterodimers (Braud et al., 1998; Lee et al., 1998) . However, HLA-E expression on CaSki, SiHa or HeLa cells was very low, in agreement with a previous report (Marin et al., 2003) . Furthermore, HLA-E expression was not significantly altered on these cells after siRNA-mediated reduction of E7 expression. No significant alteration of HLA-E expression due to E7 siRNA treatment was noted in control HaCaT cells (Supplementary Figure 3B) . HLA-E expression was also barely detectable on U2OS cells before or after induction of E7 expression (Supplementary Figure 3A) .
Several studies have shown that MHC class I expression is downregulated in high-risk HPV-positive cervical carcinoma tissues (Cromme et al., 1993 (Cromme et al., , 1994 Brady et al., 2000) . One study showed that such downregulation occurs without a corresponding reduction in MHC class I heavy chain transcripts, raising the possibility that a post-transcriptional regulatory mechanism of class I expression exists in HPV-transformed cells (Cromme et al., 1993) . However, it has been established that E7 from HPV16 and HPV18 can repress the activity of the MHC class I heavy chain promoter (Georgopoulos et al., 2000) and that HPV16 E7 is associated with the MHC class I promoter where it may recruit histone deacetylases (Li et al., 2006) . HPV18 E7 can also repress the bi-directional promoter that regulates expression of the LMP2 and TAP1 genes which encode components of the antigen presentation pathway (Georgopoulos et al., 2000) . TAP1 is involved in peptide loading of MHC class I molecules and is therefore essential for its expression at the cell surface (Abele and Tampe, 2006) . Loss of TAP expression has been reported in cervical carcinoma tissues (Cromme et al., 1994) , although this was not linked to the presence of HPV DNA. Thus, E7-mediated transcriptional or post-transcriptional reduction in TAP may explain, at least in part, the loss of cell-surface class I expression in HPV-transformed cells although it is likely that other viral gene products and cellular targets are also involved. For example, the E5 protein of human and bovine papillomaviruses localizes in the Golgi apparatus and retains MHC class I molecules (O'Brien and Campo, 2003) .
Viruses use a wide variety of mechanisms to inhibit antigen presentation (Hewitt, 2003) and MHC class I downregulation is a common feature of tumour cells (Garcia-Lora et al., 2003) . Our results demonstrate that, in HPV-associated malignancies, MHC class I downregulation is the result of an E7-mediated pathway which has probably evolved to facilitate immune evasion during viral replication.
